Search Results

You are looking at 81 - 90 of 457 items for :

  • Refine by Access: All x
Clear All
Full access

Presenter: Jens Hillengass

, serum free light chains, flow cytometry, immunoparesis, MRI, and fluorescence in situ hybridization (FISH). Clinicians should also consider the concept of evolving smoldering MM, said Dr. Hillengass, because dynamically stable markers of disease are

Full access

Peter H. Carroll and James L. Mohler

MRI. Further, they support the use of active surveillance in men identified to have low-risk cancers, linked to and compliant with the NCCN Guidelines for Prostate Cancer. Dr. Carroll acknowledged that in the 1990s and 2000s, routine screening was

Full access

L. Burt Nabors

combinations in the setting of recurrent disease. We would alert the oncology community to a couple of unique aspects concerning the use of bevacizumab in GBM. First, bevacizumab has an impact on diagnostic imaging studies, particularly MRI. A misconception

Full access

examinations, MRI evaluations, and serum biomarker assessments. All patients will be treated until radiographic or clinical evidence is seen of disease progression or unacceptable toxicity. Patients may withdraw from the study at any time. Primary Objective

Full access

Stephen B. Edge

address in controlled clinical trials. Technological Advances and Controversies A major change in breast surgery practice has been the use of MRI. Compared with other breast imaging, breast MRI may provide better information on the extent of a

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

breast cancer diagnosed by age 50 years, receive dedicated breast MRI annually. 2 ASCO and NCCN have issued guidelines stating that, after initial treatment, surveillance for recurrence in patients with stage I–III breast cancer should include periodic

Full access

Bethany L. Niell

with a breast biopsy in 2010 through 2012. Claims for high-cost imaging studies, such as CT, brain or body MRI, PET, and bone scans, in the 18-month postoperative period were included if the imaging was performed for a breast cancer indication. The

Full access

Kamran Aghayev, Frank Vrionis, and Marc C. Chamberlain

General Considerations Imaging MRI (with and without contrast) plays an essential role in the diagnosis of primary spinal cord tumors. Currently, no other imaging modality can be used alone to establish a diagnosis. Plain radiographs may show

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

, determination of tumor estrogen receptor (ER) status, and MRI as indicated. For pathology reporting, the NCCN panel endorses the College of American Pathologists' protocol for both invasive and noninvasive carcinomas of the breast. 1 The NCCN Guidelines Panel

Full access

Mark D. Tyson and Sam S. Chang

annually up to 5 years. 2 If the patient underwent a partial nephrectomy, a baseline abdominal CT, MRI, or ultrasound is recommended within 3 to 12 months of surgery, then annually for 3 years if the baseline scan is negative. Recognizing that the risk of